Diclofenac submicron particle capsules demonstrate early and sustained acute pain relief in a phase 3 study in patients following bunionectomy surgery  by Argoff, C. et al.
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S291Acknowledgment: ﬁnancial support of Top Institute Pharma (grant T1-
213-1), Anna Fonds and Nuts Ohra
568
DICLOFENAC SUBMICRON PARTICLE CAPSULES DEMONSTRATE
EARLY AND SUSTAINED ACUTE PAIN RELIEF IN A PHASE 3 STUDY
IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY
C. Argoff y, S. Silberstein z, A. Gibofsky x, S. Daniels k, S. Jensen {, C.
Young {. yAlbany Med. Coll., Albany, NY, USA; z Thomas Jefferson Univ.,
Philadelphia, PA, USA; xHosp. for Special Surgery, New York, NY, USA;
k Premier Res. Group, Ltd, Austin, TX, USA; { Iroko Pharmaceuticals, LLC,
Philadelphia, PA, USA
Purpose: Early management of acute pain may impact the severity and
duration of pain. NSAIDs are utilized to treat acute pain but have the
potential for serious dose-related gastrointestinal, cardiovascular, and
renal adverse events (AEs). Investigational submicron particle NSAIDs
using proprietary SoluMatrix technology are being evaluated to assess
the potential to provide effective pain relief at lower doses than
currently available oral NSAIDs. In a Phase 1 study, diclofenac submi-
cron particle capsules 35 mg achieved an early time to maximum
concentration, a similar maximum concentration, and lower systemic
drug exposure compared with diclofenac potassium immediate-release
tablets. In a Phase 2 study, diclofenac submicron particle capsules (18
and 35 mg) provided effective analgesia and were generally well-
tolerated in a validated post-surgical model of mild to moderate pain.
We evaluated the analgesic efﬁcacy of diclofenac submicron particle
capsules in a post-surgical model of moderate to severe pain.
Methods: This Phase 3 multi-center, double-blind study enrolled 428
patients 18-65 years of age who underwent a primary, unilateral ﬁrst
metatarsal bunionectomy with osteotomy and ﬁxation under regional
anesthesia. Patients experiencing a pain intensity rating of 40mm on
a 100mm visual analog scale (VAS) were randomized to receive diclo-
fenac submicron particle capsules (18 or 35mg; TID), celecoxib (400mg
loading dose, then 200mg BID), or placebo. The primary endpoint was
the summed pain intensity difference measured by VAS over 48 hrs
(VAS SPID-48). Secondary endpoints included the VAS pain intensity
difference (VAS PID) at various time points versus placebo.
Results: As presented recently for the primary endpoint (mean VAS
SPID-48), diclofenac submicron particle 35mg (524; P<0.001) and 18mg
(393; P¼0.01) and celecoxib (391; P¼0.011) demonstrated signiﬁcant
pain control compared with placebo. Some pain relief (mean VAS PID)
was apparent in the diclofenac submicron particle 35mg (4.52) group at
30min in contrast to the placebo (0.12) group. Pain control increased
over time for all active treatment groups. At 4h after dose administra-
tion, diclofenac submicron particle 35mg provided better pain control
(VAS PID) versus placebo (P¼0.025; Figure). At 5h after study entry,
signiﬁcant pain control was noted in the diclofenac submicron particle
35mg (9.43; P¼0.002), 18mg (8.35; P¼0.009), and celecoxib (6.62;
P¼0.032) treatment groups versus placebo (2.30; Figure).Overall, the
most frequent treatment-emergent adverse events were localized post-
procedural edema (32.7%, 140/428), nausea (29.7%, 127/428), headache
(12.9%, 55/428), and dizziness (11.7%, 50/428).
ĂConclusions: Lower-dose, submicron particle diclofenac demon-
strated better pain control at 48h (VAS SPID-48) with evidence of
analgesia as early as 30 min after administration compared with
placebo, and was generally well tolerated. These results suggest that
diclofenac submicron particle capsules are a potentially promising
therapeutic option for acute pain.569
MANAGEMENT OF PATIENTS WITH KNEE OSTEOARTHRITIS BEFORE
AND AFTER THE PHILIPPINE CLINICAL PRACTICE GUIDELINE FOR
KNEE OSTEOARTHRITIS
G.Z. Racaza, E.G. Penserga. Philippine Gen. Hosp., Taft Avenue, Manila,
Philippines
Purpose: We aim to review changes in physicians’ practice on the
management of osteoarthritis (OA) before and after the publication of
the Philippine Rheumatology Association (PRA) Clinical Practice
Guidelines (CPG) for knee OA in year 2010. Major highlights of the CPG
were advocacy of paracetamol as ﬁrst-line pharmacologic therapy fol-
lowed by tramadol, good evidence for usage of glucosamine sulfate,
limitation of NSAIDs usage, and emphasis on rehabilitation and lifestyle
modiﬁcation/advice.
Methods: This study reviewed clinical charts of patients diagnosed
with primary OA (American College of Rheumatology criteria) in the
Philippine General Hospital Arthritis Clinic from January to December
2009 and January to December 2011. Data regarding conventional
management (non-pharmacologic and pharmacologic) and comple-
mentary/alternative therapies on the ﬁrst visit were extracted.
Continuous data were described using means and standard deviations
while nominal data were described using frequencies and percentages.
T-test for two proportions were used to compare use of different
pharmacologic and alternative treatment pre- and post- CPG. P-value
less than 0.05 were considered signiﬁcant.
Results: One hundred eleven patients were included in the study (60
from 2009 and 51 from 2011). Mean age of symptom presentation and
diagnosis were 59.7 years (SD: 10.3 years) 63.2 years (SD: 9.9 years),
respectively. Majority (81.08%) were females. Mean BMI was 26.5 kg/m2
(SD: 5.03), considered obese stage I. The most common presentation
was knee pain (69.8%), majority (76.48%) of which were bilateral. There
were no signiﬁcant differences (p-value 0.723) between the mean age
between pre- (mean 59.3 years; SD 1.5 years) and post-CPG patients
(mean 60.1 years; SD 1.3 years). Likewise, there were no signiﬁcant
differences in sex (p-value 0.2529) and proportion of dyspeptics (p-
value 0.4760). Mean BMI is higher among pre-CPG patients (mean 27.9;
SD 0.78) compared to post-CPG (mean 25.69; SD 0.56) and the result is
statistically signiﬁcant (p-value 0.03). There were statistically more
patients post-CPG who had Kellgren Lawrence score of 2 compared to
pre-CPG patients. The two populations had no signiﬁcant difference
across the rest of the scores. The use of paracetamol is signiﬁcantly
higher among post-CPG patients (54/60, 90% vs pre-CPG 33/51, 64.71%;
p-value 0.0013) but the use of tramadol before and after CPG publica-
tion is not statistically signiﬁcant (p-value 0.1119). Use of NSAID (COX-1
inhibitor) and COX-2 inhibitors was signiﬁcantly lower after the CPG
publication [(5/60, 8.33% vs pre-CPG 17/51, 33.33%; p-value 0.013) and
(6/60, 10.17% vs pre-CPG 25/51, 49.02%; p-value 0.000), respectively].
Glucosamine sulfate use was slightly higher post-CPG (31/51, 51.67%)
compared to pre-CPG (25/60, 49.02%) but this difference was not
statistically signiﬁcant (p-value 0.7810). Use of non-pharmacologic
interventions was signiﬁcantly higher post-CPG (49/60, 81.67%
compared to pre-CPG 12/51, 23.53%, p value 0.0000).
Conclusion: The published CPG by the PRA signiﬁcantly changed the
physicians’ management of patients with OA. Whether it has impacted
the patients’ symptoms, quality of life and overall satisfaction, however,
remains to be determined and can be the subject of studies in the near
future.570
A SINGLE INTRA-ARTICULAR INJECTION WITH IL-4 PLUS IL-10
AMELIORATES BLOOD-INDUCED CARTILAGE DEGENERATION IN
HAEMOPHILIC MICE
L. van Vulpen, M.E. van Meegeren, G. Roosendaal, K. Coeleveld, L.
Nieuwenhuizen, S.C. Mastbergen, F.P. Lafeber. UMC Utrecht, Utrecht,
The Netherlands
Purpose: Exposure of joint cartilage to blood can occur after joint
trauma, during or after major joint surgery, or due to hemophilia. This
ultimately leads to joint damage, both by direct effects of blood on
cartilage and via synovial inﬂammation (Lafeber et al., Haemophilia
2008). The cytokines interleukine (IL)-4 and IL-10 are known as
modulatory cytokines. A combination of IL-4 plus IL-10 protects against
blood-induced cartilage damage in vitro (van Meegeren et al., Osteoar-
thritis & Cartilage 2012). It has been hypothesized that the combination
